Treatment for demyelinating disease
AssigneeMedical Research Council
InventorsLars Fugger, Manuel Friese
Life of this patent
Estimating the term…
Abstract
The invention relates to a method of treatment or prophylaxis of demyelinating disease, in particular the neurodegenerative phase of demyelinating disease, which comprises administration of an acid sensing ion channel (ASIC) antagonist. The invention also relates to a pharmaceutical composition comprising an ASIC antagonist in combination with an additional therapeutic agent, in particular an anti-inflammatory or immunmodulatory agent.
Claims5
A method of reducing axonal degeneration in an individual having multiple sclerosis, comprising administering an ASIC1 receptor antagonist to the individual, wherein the ASIC1 antagonist comprises 3,5-diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide or a pharmaceutically acceptable salt or solvate thereof.
Dependencies are inferred from the claim text.